ReviewJournal of neurochemistry2019
Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.
Review in Journal of neurochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- An RNA biomarker panel for the diagnosis of Alzheimer's disease from whole blood.Alzheimer's research & therapy · 2026Article
- Proteome-Based Biomarkers for Alzheimer's Disease: Old Acquisitions and Innovative Proposals.International journal of molecular sciences · 2025Review
- Glycosphingolipids in Dementia: Insights from Mass Spectrometry and Systems Biology Approaches.Biomedicines · 2025Review
- Expanding our understanding of synucleinopathies: proteinopathy, proteinopenia, and lipidopathy.The FEBS journal · 2025Review
- LC-MS determination of Nicotiana benthamiana host plant proteins in the drug products of recombinant plant-produced pembrolizumab.Scientific reports · 2025Article
- Advances in Circulating Biomarkers for Neurodegenerative Diseases, Traumatic Brain Injuries, and Central Nervous System Tumors.Annals of laboratory medicine · 2025Review
- "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- ProPickML: Advancing Clinical Diagnostics with Automated Peak Picking in Label-Free Targeted Proteomics.Journal of proteome research · 2025Article
- Alzheimer's disease: where do we stand now and what are the strategic interventions?Frontiers in cellular neuroscience · 2025Review
- DNAzyme-based faithful probing and pulldown to identify candidate biomarkers of low abundance.Nature chemistry · 2024Article
- Application of multi-omics in the study of traditional Chinese medicine.Frontiers in pharmacology · 2024Review
- Proteomics identifies lipocalin-2 in neonatal inflammation associated with cerebrovascular alteration in mice and preterm infants.iScience · 2023Article
- The Potential ofGenes · 2023Article
- Lipidomics and proteomics: An integrative approach for early diagnosis of dementia and Alzheimer's disease.Frontiers in genetics · 2023Review
- Mechanistic insight into female predominance in Alzheimer's disease based on aberrant protein S-nitrosylation of C3.Science advances · 2022Article
- Global, in situ analysis of the structural proteome in individuals with Parkinson's disease to identify a new class of biomarker.Nature structural & molecular biology · 2022Article
- Analysis of human brain tissue derived from DBS surgery.Translational neurodegeneration · 2022Article
- Applications of Tandem Mass Spectrometry (MS/MS) in Protein Analysis for Biomedical Research.Molecules (Basel, Switzerland) · 2022Review
- Applications of spatially resolved omics in the field of endocrine tumors.Frontiers in endocrinology · 2022Review
- Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.Journal of neurochemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Accurate, reliable, and objective biomarkers for Alzheimer's disease (AD), Parkinson's disease (PD), and related age-associated neurodegenerative disorders are urgently needed to assist in both diagnosis, particularly at early stages, and monitoring of disease progression. Technological advancements in protein detection platforms over the last few decades have resulted in a plethora of reported molecular biomarker candidates for both AD and PD; however, very few of these candidates are developed beyond the discovery phase of the biomarker development pipeline, a reflection of the current bottleneck within the field. In this review, the expanded use of selected reaction monitoring (SRM) targeted mass spectrometry will be discussed in detail as a platform for systematic verification of large panels of protein biomarker candidates prior to costly validation testing. We also advocate for the coupling of discovery-based proteomics with modern targeted MS-based approaches (e.g., SRM) within a single study in future workflows to expedite biomarker development and validation for AD and PD. It is our hope that improving the efficiency within the biomarker development process by use of an SRM pipeline may ultimately hasten the development of biomarkers that both decrease misdiagnosis of AD and PD and ultimately lead to detection at early stages of disease and objective assessment of disease progression. This article is part of the special issue "Proteomics".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.